Want to see MDCX full AI Analyst Report?
MDCX Stock Chart & Stats
$0.37
-$0.01(-3.70%)
At close: 4:00 PM EDT
$0.37
-$0.01(-3.70%)
Day’s Range― - ―
52-Week Range$0.24 - $3.05
Previous CloseN/A
Volume1.03M
Average Volume (3M)1.60M
Market Cap
$17.17M
Enterprise Value$29.15
Total Cash (Recent Filing)$15.17M
Total Debt (Recent Filing)$15.25M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Nov 20, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding63,180,610
10 Day Avg. Volume1,268,688
30 Day Avg. Volume1,603,994
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-391.45
Price to Sales (P/S)0.00
P/FCF Ratio-1.16
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.97Price Target Upside972.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline AdvancementProgression of both lead programs toward late-stage development could expand the company’s future commercial opportunity and create multiple regulatory milestones, provided execution and trial outcomes support eventual approvals.
Secured Funding For DevelopmentThe financing provides resources to continue clinical development and pursue business initiatives over the coming periods, reducing immediate funding uncertainty even though the associated security interests and repayment terms remain restrictive.
Lower Current Debt BurdenLower reported debt and a larger asset base offer some balance-sheet support relative to the prior period, potentially improving financial flexibility while the company advances its pipeline, although negative equity remains a major constraint.
Bears Say
No Revenue And Widening LossesThe absence of revenue leaves the company dependent on future product development and commercialization, while accelerating losses show that spending is rising without an offsetting operating base or demonstrated operating leverage.
Persistent Cash BurnSustained operating and free-cash-flow deficits require recurring external funding to maintain operations and clinical programs, increasing dilution, financing-cost and execution risks until revenue generation becomes established.
Capital Structure And Listing RiskNegative equity limits financial flexibility, while Nasdaq compliance pressure and lender claims over company assets increase strategic constraints. The approved share consolidation may aid compliance but also signals continuing capital-structure stress.
Medicus Pharma Ltd News
MDCX FAQ
What was Medicus Pharma Ltd’s price range in the past 12 months?
Medicus Pharma Ltd lowest stock price was $0.24 and its highest was $3.05 in the past 12 months.
What is Medicus Pharma Ltd’s market cap?
Medicus Pharma Ltd’s market cap is $17.17M.
When is Medicus Pharma Ltd’s upcoming earnings report date?
Medicus Pharma Ltd’s upcoming earnings report date is Nov 20, 2026 which is in 89 days.
How were Medicus Pharma Ltd’s earnings last quarter?
Medicus Pharma Ltd released its earnings results on Aug 13, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.128 by -$0.082.
Is Medicus Pharma Ltd overvalued?
According to Wall Street analysts Medicus Pharma Ltd’s price is currently Undervalued.
Does Medicus Pharma Ltd pay dividends?
Medicus Pharma Ltd does not currently pay dividends.
What is Medicus Pharma Ltd’s EPS estimate?
Medicus Pharma Ltd’s EPS estimate is -0.13.
How many shares outstanding does Medicus Pharma Ltd have?
Medicus Pharma Ltd has 63,180,610 shares outstanding.
What happened to Medicus Pharma Ltd’s price movement after its last earnings report?
Medicus Pharma Ltd reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.128. Following the earnings report the stock price went up 6.949%.
Which hedge fund is a major shareholder of Medicus Pharma Ltd?
Currently, no hedge funds are holding shares in MDCX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicus Pharma Ltd
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
MDCX Stock 12 Month Forecast
Average Price Target
$3.97
▲(972.07% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Palatin Technologies
―
Daré Bioscience
―
Lipocine
―
Citius Pharmaceuticals
―
Ownership Overview
― Insiders
<0.01% Mutual Funds
2.84% Other Institutional Investors
97.15% Public Companies and
Individual Investors